Dr. Martens plc (LON:DOCS - Get Free Report) insider Ije Nwokori acquired 194 shares of the stock in a transaction dated Friday, July 11th. The stock was acquired at an average price of GBX 77 ($1.03) per share, for a total transaction of £149.38 ($200.56).
Ije Nwokori also recently made the following trade(s):
- On Wednesday, June 11th, Ije Nwokori bought 189 shares of Dr. Martens stock. The stock was acquired at an average cost of GBX 79 ($1.06) per share, with a total value of £149.31 ($200.47).
Dr. Martens Trading Down 0.6%
Shares of DOCS traded down GBX 0.45 ($0.01) during mid-day trading on Tuesday, hitting GBX 79.35 ($1.07). 1,135,357 shares of the company's stock traded hands, compared to its average volume of 2,146,888. The firm has a market capitalization of £770.30 million, a P/E ratio of 11.25, a PEG ratio of 6.40 and a beta of 0.11. The business's 50-day moving average price is GBX 68.06 and its 200-day moving average price is GBX 63.91. Dr. Martens plc has a 1 year low of GBX 43.02 ($0.58) and a 1 year high of GBX 83.30 ($1.12). The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27.
Dr. Martens (LON:DOCS - Get Free Report) last issued its quarterly earnings data on Thursday, June 5th. The company reported GBX 2.40 ($0.03) earnings per share for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. As a group, sell-side analysts forecast that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.
Analysts Set New Price Targets
Several research analysts have commented on the company. Royal Bank Of Canada lowered their target price on Dr. Martens from GBX 7,000 ($93.98) to GBX 6,000 ($80.56) and set a "sector perform" rating for the company in a research note on Monday, May 19th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Dr. Martens in a research note on Friday.
Check Out Our Latest Stock Analysis on DOCS
Dr. Martens Company Profile
(
Get Free Report)
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking
for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage
and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of
empowerment and their own individual attitude.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
See Also
Before you consider Dr. Martens, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.
While Dr. Martens currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
